First clinical case of a locally acquired carbapenem-resistant VIM-1 metallo-β-lactamase in Pseudomonas aeruginosa in Australia

Medical Journal of Australia

Volumn 191, Issue 5, 2009, Pages 289-

  Merlino, John ^a   Stokes, Harold W ^b   Cheong, Elaine Y L ^a   Gottlieb, Thomas ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; BACTERIAL PROTEIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; METALLO BETA LACTAMASE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; PREDNISONE; PROTEIN VIM 1; TIMENTIN; UNCLASSIFIED DRUG;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AUSTRALIA; BACTERIUM ISOLATION; CASE REPORT; HUMAN; LETTER; MALE; NONHUMAN; PROSTHESIS INFECTION; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS;

EID: 71249105472     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02791.x     Document Type: Letter

References (4)

1. IMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41: 1549-1556.
2. Espedido BA, Thomas LC, Iredell JR. Metallo-β-lactamase or extended-spectrum β-lactamase: a wolf in sheep's clothing. J Clin Microbiol 2007; 45: 2034-2036. (Pubitemid 46933955)
3. Mesaros N, Nordmann P, Plésiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007; 13: 560-578. (Pubitemid 46730662)
4. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-325.